Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Alternative RNA Splicing

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources.

The Lancet. Haematology·2026

Same author

TNFα signaling restores steady-state hematopoiesis in a TNFαKO mouse model of anemia of inflammation.

Blood·2025

Same author

Effective gene therapy for metachromatic leukodystrophy achieved with minimal lentiviral genomic integrations.

Molecular therapy. Nucleic acids·2025

Same author

CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Same author

Selecting patients with sickle cell disease for gene addition or gene editing-based therapeutic approaches: Report on behalf of a joint EHA Specialized Working Group and EBMT Hemoglobinopathies Working Party consensus conference.

HemaSphere·2025

Same author

Restoring hematopoietic stem and progenitor cell function in <i>Fancc</i> <sup></sup> mice by <i>in situ</i> delivery of RNA lipid nanoparticles.

Molecular therapy. Nucleic acids·2025

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Future alternative therapies for β-thalassemia.

Stefano Rivella¹, Eliezer Rachmilewitz

¹Weill College Medical Center, Department of Pediatrics, Division of Hematology, Oncology, 515 E 71st Street, S702, New York, NY 10021, USA, Tel.: +1 212 746 4941, , str2010@med.cornell.edu.

Expert Review of Hematology

|February 23, 2010

Summary

Beta-thalassemia, a genetic blood disorder, causes anemia and iron overload. Recent research offers new therapeutic avenues to manage complications and reduce transfusion dependency.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Related Experiment Videos

Last Updated: Jun 16, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Area of Science:

Hematology
Genetics
Molecular Biology

Background:

Beta-thalassemia is an inherited disorder caused by mutations in the beta-globin gene.
It leads to anemia, iron overload, and ineffective erythropoiesis, necessitating blood transfusions.
While screening has reduced cases in some regions, it's a growing global health issue.

Purpose of the Study:

To review the current understanding of beta-thalassemia's molecular aspects and pathophysiological challenges.
To highlight recent advancements in therapeutic approaches for beta-thalassemia.

Main Methods:

Review of molecular biology, pathophysiology, and recent therapeutic studies on beta-thalassemia.
Analysis of disease progression, complications, and management strategies.

Main Results:

Understanding molecular mechanisms has improved screening and prenatal diagnosis, reducing major beta-thalassemia births in certain areas.
Persistent challenges include ineffective erythropoiesis, iron overload, oxidative stress, splenomegaly, and thrombosis.
Novel therapeutic strategies show promise in addressing these issues and minimizing transfusion needs.

Conclusions:

Despite progress, beta-thalassemia remains a significant worldwide clinical problem with complex pathophysiology.
Emerging therapies offer hope for improved management and reduced reliance on blood transfusions.
Further research into molecular mechanisms is crucial for developing advanced treatments.